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Abstract: Fe3O4–Au core–shell magnetic-plasmonic nanoparticles are expected to combine both
magnetic and light responsivity into a single nanosystem, facilitating combined optical and
magnetic-based nanotheranostic (therapeutic and diagnostic) applications, for example, photothermal
therapy in conjunction with magnetic resonance imaging (MRI) imaging. To date, the effects
of a plasmonic gold shell on an iron oxide nanoparticle core in magnetic-based applications
remains largely unexplored. For this study, we quantified the efficacy of magnetic iron oxide
cores with various gold shell thicknesses in a number of popular magnetic-based nanotheranostic
applications; these included magnetic sorting and targeting (quantifying magnetic manipulability and
magnetophoresis), MRI contrasting (quantifying benchtop nuclear magnetic resonance (NMR)-based
T1 and T2 relaxivity), and magnetic hyperthermia therapy (quantifying alternating magnetic-field
heating). We observed a general decrease in magnetic response and efficacy with an increase of the
gold shell thickness, and herein we discuss possible reasons for this reduction. The magnetophoresis
speed of iron oxide nanoparticles coated with the thickest gold shell tested here (ca. 42 nm) was only
ca. 1% of the non-coated bare magnetic nanoparticle, demonstrating reduced magnetic manipulability.
The T1 relaxivity, r1, of the thick gold-shelled magnetic particle was ca. 22% of the purely magnetic
counterpart, whereas the T2 relaxivity, r2, was 42%, indicating a reduced MRI contrasting. Lastly,
the magnetic hyperthermia heating efficiency (intrinsic loss power parameter) was reduced to ca.
14% for the thickest gold shell. For all applications, the efficiency decayed exponentially with increased
gold shell thickness; therefore, if the primary application of the nanostructure is magnetic-based,
this work suggests that it is preferable to use a thinner gold shell or higher levels of stimuli to
compensate for losses associated with the addition of the gold shell. Moreover, as thinner gold shells
have better magnetic properties, have previously demonstrated superior optical properties, and are
more economical than thick gold shells, it can be said that “less is more”.
Keywords: magnetic-plasmonic nanoparticles; nuclear magnetic resonance; magnetic hyperthermia;
magnetic drug delivery; gold shell; magnetic manipulation; nanotheranostics
1. Introduction
Inorganic nanomaterials such as gadolinium [1], iron oxide [2], silica [3], and gold [4] are becoming
increasingly popular in nanotheranostic applications (combined therapeutics and diagnostics),
particularly as imaging agents, drug deliverers, and hyperthermia agents. It is hypothesized that
combining materials into a single nanoplatform strengthens the physical properties of the nanosystem.
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One such example is the combination of a magnetic and plasmonic material into a single hybrid
nanostructure. Ideally, this magnetic-plasmonic nanoparticle will maintain the physical properties of
each material when combined in the bi-functional nanomaterial. A plasmonic gold shell facilitates
a number of optical-based applications, including surface-enhanced Raman scattering (SERS) [5],
photothermal activity [6], and optical imaging contrast [7]; and these applications could be combined
with magnetic-based applications if a magnetic core is used. For this study, we measured how a
gold shell grown on a magnetite core affects the nanoparticle efficacy in various magnetic-based
nanotherapeutic applications to understand the implications of magnetic-plasmonic nanoparticle
hybridization. We found that, as prepared, the core–shell nanoparticle remains meaningfully efficient
in magnetic-based applications for gold thicknesses of approximately ≤4 nm with iron oxide cores of
ca. 20 nm.
Magnetic nanomaterials are at the forefront of inorganic nanotheranostics, particularly in
diagnostics as contrast agents in nuclear magnetic resonance (NMR)-based applications, including
magnetic resonance imaging (MRI) [8] and NMR-based biosensing [9], and in therapeutics as drug
delivery [10,11] and hyperthermia agents [12]. The ability to manipulate or interact with material
at the nanoscale with external stimuli is of utmost interest [13]. Magnetic nanomaterials may be
manipulated by an external magnetic field, facilitating magnetic flux-driven drug delivery [10] for
therapeutics, and magnetic separation of cells or blood [14] for diagnostics. Many types of magnetic
nanoparticles exist, but superparamagnetic iron oxide (magnetite) nanoparticles are arguably the most
prevalent in nanotheranostics [15]. Superparamagnetism is a type of magnetism that exists in nanoscale
single magnetic domain ferri- or ferromagnetic materials. Superparamagnetic nanoparticles have
two stable antiparallel orientations of the magnetic moment, with an energy barrier separating these
orientations. In the absence of an external magnetic field and at temperatures where the energy barrier
is less than the thermal fluctuation energy, the magnetic moment regularly flips direction leading to a
net magnetization averaged to zero. In other words, superparamagnetic nanoparticles exhibit a net
zero magnetic moment at certain temperatures in the absence of a magnetic field. However, when a
magnetic field is applied, the magnetic moments align with the field, acting like a paramagnet but with
higher magnetic susceptibility. Non-superparamagnetic magnetic nanoparticles experience strong
interparticle magnetic forces in the absence of an external field that leads to aggregation. By contrast,
superparamagnetic nanoparticles do not experience these strong interparticle magnetic forces in the
absence of a magnetic field, and thus may be colloidally stable, a big advantage in many applications.
Along with superparamagnetic iron oxide nanoparticles, plasmonic nanoparticles are popular in
the field of nanotheranostics [16–18]. A plasmon is a collective oscillation of the local electron density
of a material; near optical resonance, this local electron density coherently oscillates with incident
electromagnetic (light) excitation. This leads to enhanced optical absorption, scattering, and local electric
field, which can be exploited in several applications including imaging [19,20] and sensing [21] and in
drug delivery [22]. Furthermore, similar to magnetic nanomaterials, they are effective hyperthermia
agents in plasmonic photothermal therapy [23]. When these plasmonic nanoparticles are excited by
light near or at their optical resonance frequency, the mobile carriers dissipate their energy in the form
of heat, which is then diffused into the surrounding area. Gold is typically chosen as the plasmonic
material in bioapplications due to its stability, plasmon resonance located in the visible/near-infrared
(NIR), and biocompatibility [24].
Many geometries of magnetic-plasmonic nanostructure exist, but to take advantage of the
superior stability and biocompatibility of gold, the exterior should be gold, i.e., a core–shell structure.
Magnetite–gold core–shell nanoparticles have also been used for photothermal activity [25],
SERS enhancement [26], optical imaging contrast [27], interesting optical effects [28], enhanced Faraday
rotation [29], and optical modulation in low-field magnetic relaxation [30] and have demonstrated
good biocompatibility [31]. The gold shell in these reports varies dramatically, from thin or incomplete
to thick gold shells. Ideally, such magnetic-plasmonic nanoparticles could be used in combined
nanotheranostic applications, for example, photothermal therapy in combination with MRI imaging,
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simultaneous optical imaging and magnetic hyperthermia, or magnetic separation combined with
SERS. From our previous work [28], we found that thicker gold shells led to increased light scattering,
and we would also expect decreased cytotoxicity [32] and circulation half-life [33] for this nanostructure.
Meanwhile, thin-to-moderate gold shells facilitated spectrally selective photothermal activity due to
the emergence of a spectral drift [28]. For this study, we explored the effects of the plasmonic gold shell
in three notable magnetic-based applications, by comparing five different stages of magnetic-plasmonic
nanoparticle with varied gold shell thickness. The three popular nanotheranostic applications
considered were magnetic separation and targeting ability (by quantifying magnetophoresis), T1 and T2
MRI contrasting (by quantifying NMR relaxivity), and magnetic hyperthermia activity (by monitoring
the heat generation in an alternating magnetic field).
2. Materials and Methods
2.1. Synthesis of Multistage Magnetic-Plasmonic Nanoparticles
First, 20.5 ± 1.3 nm diameter commercial oleic acid-capped iron oxide nanoparticles (Ocean
NanoTech, San Diego, CA, USA) were amine functionalized by ligand exchange using (3-aminopropyl)
triethoxysilane (APTES) and using a protocol modified from [34], to aid further functionalization
and improved biocompatibility [35] (denoted O, black in graphs). Next, tetrakis(hydroxymethyl)
phosphonium chloride (THPC)-reduced gold nanoseeds prepared by the Duff method [36] were
grafted onto the iron oxide core giving a core–satellite or seeded stage (Os, red). The gold-seeded
iron oxide nanoparticles were then subjected to three iterative gold reductions using a gold-plating
solution and formaldehyde reduction modified from [37], yielding three further stages of gold growth
called R1 (green), R2 (blue), and R3 (orange) throughout, and had a diameter determined by TEM of
28.5 ± 2.2, 42.1 ± 10.3, and 103.7 ± 16.9 nm, respectively. To read further details about the synthesis of
these multistage magnetic-plasmonic nanostructures and see transmission electron micrographs of the
various stages, please see our earlier work in [24]. To aid the comparison between gold-coated stages
and uncoated iron oxide, the mass of iron oxide (i.e., the number of nanoparticles) was kept constant in
this work.
2.2. Magnetophoresis
To conduct optical tracking of magnetophoresis, a deuterium–halogen UV–VIS–NIR light source
(DH2000-BAL, Ocean Optics, Orlando, FL, USA) using only halogen as the light source was passed
through a quartz cuvette (CV10Q3500, Thorlabs, Newton, NJ, USA) containing the suspended
nanoparticles. The transmitted light was focused onto a flame spectrometer (Ocean Optics), which was
paired with OceanView software (Version 1.6.7, Ocean Optics). The probed area was a cylindrical
region in the cuvette with a 5 mm diameter and a 10 mm height, centered 70 mm above a magnet
(neodymium, 10 mm × 10 mm × 10 mm). The magnet’s distance-dependent magnetic flux density was
measured using a gaussmeter. The extinction peak was monitored temporally, and a linear fit of the
peak extinction is used to monitor magnetophoresis.
2.3. NMR T1 and T2 Relaxation Measurements
To conduct T1 and T2 measurements of the multistage magnetic-plasmonic nanostructures,
a benchtop NMR (1H Spinsolve 60 MHz, Magritek, Malvern, PA, USA) was used. The magnetic field
strength was 1.5 Tesla, and the proton Larmor frequency was 60MHz. To track the effect of the gold
shell on the magnetic nanoparticle relaxivity, the 1H (water) peak at ≈4.8 ppm was monitored.
T1 measurements were conducted using an inversion recovery pulse sequence, starting with the
shortest inversion delay; a series of experiments were conducted with the inversion delay stepped
linearly to the maximum inversion time. Two scans of 1.6 s acquisition time (8192 points, dwell time
of 200 µs), repetition time of 7 s, and a varied inversion time of ≈5 s with 21 steps were taken for the
T1 measurements.
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T2 measurements were made using a Carr–Purcell–Meiboom–Gill (CPMG) pulse sequence,
starting with the shortest echo time τ; a series of measurements were conducted where 180-degree
pulses were stepped linearly, ending with the final (variable) echo time. Four scans with an acquisition
time of 0.4 s (8192 points, 50 µs dwell time), 4 s repetition time, 20 steps with a CPMG echo time of
0.2 ms, and a varied final echo time of ≈2 s were taken for the T2 measurements. The 90◦ pulse width
was 7 ms for both measurements.
2.4. Magnetic Hyperthermia
In this research, a Flexitune induction heater (Radyne, Wokingham, UK) was used with a
water-cooled homemade copper coil, generating a 100 mT alternating magnetic field, with a frequency
of 20 kHz. Induction heaters are typically used to heat a conductive material by eddy currents.
Induction heaters are simply AC passed through an inductor (e.g., coil), thus producing an alternating
magnetic field, per Ampere’s law. A calibrated A655sc (FLIR, Wilsonville, OR, USA) infrared camera
was used to monitor the magnetic field-induced hyperthermal activity, noncontact. Aqueous solutions
of the various stages of magnetic-plasmonic nanoparticles in an Eppendorf tube (Eppendorf, Hamburg,
Germany) (at a fixed concentration of 0.2 mg/mL of iron oxide) were suspended inside the cooled
copper coil (noncontact) using a plastic mount. It is important to note that these measurements were
not conducted under adiabatic conditions (i.e., there was a loss to the environment) unlike many other
magnetic hyperthermia measurements [38], which are thermally insulated.
3. Results
To determine whether a gold coating affects the efficacy of magnetic nanoparticles in various
magnetic-based nanotheranostic applications, Fe3O4–Au nanoparticles were synthesized with various
stages of gold growth (see Section 2.1 for details). An illustration of the various nanoparticle stages is
shown in Figure 1.
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Figure 1. Illustration of the various forms and thicknesses of magnetic-plasmonic nanoparticles studied
for this paper. From left, the (3-aminopropyl) triethoxysilane (APTES) functionalized iron oxide (Fe3O4),
called O throughout. Next, the Fe3O4 nanoparticles functionalized with gold seeds, Os. Middle,
the Fe3O4–Au gold-plated nanoparticle after one gold reduction, R1. R2 is the magnetic-plasmonic
nanoparticle after two gold reductions and, lastly, R3, after three gold reductions. Reproduced with
permission from [28]; Copyright The Royal Society of Chemistry, 2020.
3.1. Magnetophoresis
Magnetic guidance or translation of magnetic (or hybrid magnetic) nanoparticles is vital
in facilitating magnetic flux-driven drug delivery, magnetic cell or blood sorting, and magnetic
field-guided therapy. Magnetic anoparticles suspended in fluid travel toward the highest magnetic
field gradient; this moveme t is called mag etophoresis. A higher magnetophoresis speed is
preferable for ost applications and has been achieved by using a stronger magnetic field gradient,
higher nano article mag etization or concentration, nanoparticle shape a isotropy [39], and surface
charge [40]. Considerable work in the magnetophoresis of various magnetic (and magnetic-plasmonic)
structures has been carried out [41–43]. Furt ermore, the addition of a nonmagnetic silica [44,45] and
polymer [43] shell has been shown to decrease the magnetophoretic mobility of magnetite nanoparticles.
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Thus, if a polymer/silica shell affects the magnetophoresis, it is reasonable to hypothesize that a gold
shell would also hamper this motion.
The magnetophoretic force, FM, exerted on a magnetic particle by an external magnetic field
is dependent on the magnetic particle volume, Vp, the magnetization of the nanoparticle, Mp,
the permeability of free space, µ0, and the magnetic field strength, H, at the particle location per [46,47]:
FM = µ0VpMp. ∇H (1)
Equation (1) is sufficient for non-interacting (noncooperative) high magnetic field gradient
magnetophoresis. Drag and magnetic interaction forces should be considered in low magnetic field
gradient magnetophoresis. For low magnetic field gradient (<100 T/m) magnetophoresis, as is the
case here, typically magnetic particles cooperate by clustering together into chain-like structures while
moving in the gradient, and this assembly accelerates the magnetophoresis transport [48,49]. This is
likely due to the coupling of the individual magnetic moments of the nanoparticles into a new and
larger effective magnetic moment. Furthermore, the drag force (friction) experienced by the assembled
nanoparticles would be reduced per the slender-body theory [50]. Magnetic dipolar interaction forces
that facilitate this magnetic assembly are increased when the nanoparticles are not colloidally stable
and are in high concentrations (due to increased probability of proximity).
The magnetic saturation of Fe3O4–Au nanoparticles has been reported to be decreased compared to
uncoated Fe3O4 by varying degrees from ≈10% to 70% [51–56], likely a result of increased gold-to-iron
oxide mass ratio and magnetic shielding by the diamagnetic gold shell [57–59]. This reduced magnetic
saturation has also been reported for other materials with increased shell thickness, including gold
shells on cobalt nanoparticles [60] and silica shells on FeNi nanoparticles [61]. On the contrary,
there are reports of increased magnetic saturation with the addition of a gold shell on Fe3O4 [62,63],
and the authors hypothesized that conduction electrons are trapped, which induces an orbital moment.
A reduction of magnetic saturation reduces the value Mp can reach, thus leading to a reduction in
the magnetic force causing the translation of the nanoparticles to the magnet. As the gold shell on
the Fe3O4 core was associated with a reduced saturation, we anticipated a reduced magnetic force
and magnetophoresis.
In this work, the magnetophoresis of the multistage magnetic-plasmonic nanoparticles was
monitored by optical extinction, per the experimental schematic seen in Figure 2A. In this experiment,
the concentration of iron oxide (and thus, the number of nanoparticles) was kept constant. Therefore,
the volume of magnetic material is constant, but the percentage per particle varies with each stage
(see Table 1). Collimated light is passed through the cuvette containing the nanoparticles, which is
then focused onto a fiber spectrometer. A permanent magnet is placed below the cuvette, with a
distance-dependent magnetic flux density seen in Figure 2B. The probed area is a cylindrical region in
the cuvette with a 5 mm diameter and a 10 mm height, centered 70 mm above the magnet. As the
nanoparticles migrate toward the magnet (due to magnetic forces) and leave the probe area, the optical
extinction decreases. The peak optical extinction was tracked during magnetophoresis and a linear fit
was added (see Figure 2C). Further experimental details are given in the experimental Section 2.1.
From Figure 2C and Table 1, increasing the gold shell thickness leads to a significantly longer
time to magnetically separate, i.e., decreased speed of magnetophoresis. The iron oxide nanoparticles
without any gold coating take approximately 12 min to migrate out of the probed area of the solution.
With the addition of gold, the magnetic separation time increases, eventually reaching 1421 min for
the thickest gold shell. Thus, thinner gold shells are likely preferable for applications that require
reasonable responsivity to the external magnetic field. Alternatively, much larger magnetic field
gradients would be required to use these thick gold-shelled nanoparticles in such applications. It is
likely a combination of a reduced magnetic saturation and loss of cooperative behavior of the thickly
gold-coated nanoparticles that leads to reduced magnetophoresis. Furthermore, an increased drag
force would be experienced by larger nanoparticles.
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light source and spectrometer to monitor the diffusion of the nanoparticles to a permanent magnet.
(B) The distance-dependent agnetic flux density of the permanent magnet used in this experiment,
with the dashed line representing the probe height. (C) The magnetophoresis of the various stages of
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Table 1. Overview of the key findings in this work for the five stages of nanoparticle. Percentages in










Nanoparticle total diameter (nm) [28] 20.5 ± 1.3 O + ~3 nm seeds 28.5 ± 2.2 42.1 ± 10.3 103.7 ± 16.9
Shell thickness (nm) [28] - - ≈4 ≈10.8 ≈41.6
Zeta Potential (mV) [28] 0.0 ± 4.1 −10.0 ± 6.8 −27.3± 2.8 −22.4 ± 2.1 −22.1 ± 3.2
Magnetophoresis time (min) 12 326 498 636 1421
Magnetophoresis speed, vmag (µm/s) 9.7 0.4 (4.1%) 0.2 (2.1%) 0.2 (2.1%) 0.1(1%)
T1 relaxivity r1 (mM/s) 0.9 0.7 (77.8%) 0.7 (77.8%) 0.3 (33.3%) 0.2 (22.2%)
T2 relaxivity r2 (mM/s) 32.7 21.9 (67%) 15.4 (47.1%) 15.1 (46.2%) 13.6 (41.6%)
Relaxivity ratio r2/r1 35.6 30.6 (86%) 23.3 (65.4%) 51.5 (144.7%) 55.5 (155.9%)
Max. temperature 3.4 2.1 (61.8%) 1.5 (44.1%) 0.3 (8.8%) 0.1 (2.9%)
Initial 60 s ∆T/∆t (m ◦C/s) 18.8 11.7 (62.2%) 6.2 (33%) 1.7 (9%) 1.3 (6.9%)
Specific power absorption (SPA) (W/g) 93.7 58.3 (62.2%) 30.9 (33%) 8.5 (9.1%) 6.5 (6.9%)
Intrinsic loss power parameter (ILP) (H m2/kg) 0.7 0.5 (71.4%) 0.2 (28.6%) 0.1 (14.3%) 0.1 (14.3%)
It should be noted that the surface charge of the nanoparticles may also affect the interaction
between nanoparticles. Zeta potential measurements of the various stages of nanoparticle are
given in Table 1, indicating good colloidal stability for R1, R2, and R3. Temperature and pH were
constant throughout.
3.2. NMR/MRI Contrast Agent
MRI is a well-known non-ionizing technique that uses radio waves along with strong magnetic
fields and gradients to conduct biological diagnostic imaging. MRI imaging is based on NMR principles,
where certain atomic nuclei (typically hydrogen) undergo Larmor precession in a strong external
magnetic field and, when the Larmor precession frequency of the nuclear magnet resonates with that
of an incoming radio wave (RF pulse), energy is absorbed from the radio wave. Protons may align in
two energy eigenstates, low and high energy, separated by a small splitting energy. At equilibrium,
most protons reside in the low energy state (aligned with the external magnetic field) and a net
polarization parallel to the external field. An incident resonant RF pulse may lead to the polarization
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vector either tipping sideways (90◦ pulse) or reversing (180◦ pulse), and the protons come into phase
with the pulse and one another (phase coherence). In response to the RF pulse, we may consider
two relaxations to equilibrium, namely spin–lattice (also known as T1 or longitudinal relaxation) and
spin–spin (also known as T2 or transverse relaxation). The recovery of the longitudinal magnetization
relaxation (Mz) to its thermal equilibrium value (Mz,eq) is called the T1 (spin–lattice) relaxation; as the
T1 relaxation is related to the redistribution of the spins to the low energy state (thermal equilibrium),
energy is dissipated to the surroundings (lattice). T2 relaxation involves the recovery of the equilibrium
state dephased spin; therefore, the magnetization vector perpendicular (transverse) to the static
magnetic field is considered, Mxy.
A downfall of MRI biological imaging is its low sensitivity. To combat low sensitivity, a contrast
agent is commonly employed to selectively alter the relaxation time of the nuclei. As the magnetic
relaxation of the nuclei varies with the square of the magnetic dipole moment, gadolinium (Gd3+)
with its seven unpaired electrons (high magnetic moment) is often used in chelated form to enhance
MRI T1 contrast. However, there are concerns regarding the safety of these gadolinium-based contrast
agents [64]. Superparamagnetic nanoparticles have been proposed as an alternative, but rather mostly
for T2 image contrast.
In terms of MRI, a local reduction (shorter time) in either the T1 relaxation (positive contrast)
or T2 relaxation (negative contrast) results in better image contrast. As the T1 and T2 times are
concentration-dependent, we define relaxivities as a function of iron concentration, i.e., r1 and r2.
The longitudinal relaxivity r1 is said to depend on the molecular tumbling time, proton residence
lifetime, and coordinating number, while the transverse relaxivity r2 is proportional to the square of the
magnetic nanoparticle radius and the magnetic saturation [65]. As the T1 relaxation is associated with
inner-sphere mechanisms (chemical energy exchange), superparamagnetic nanoparticles are instead
more effective in T2 applications.
In the case of magnetic core–nonmagnetic shell particles, the magnetic field experienced by the
water protons (T2) and the degree of chemical exchange (T1) lessens with increased shell thickness.
Furthermore, if the nanoparticles are aggregated or assembled, worse r1 contrast due to reduced surface
area and improved r2 contrast owing to the coupling of the magnetic moments are expected [66].
A relaxivity ratio (r2/r1) is often used as another measure of contrast agent usefulness. An optimal
negative contrast agent (T2) would have a high r2/r1 ratio along with a high r2 value. If this ratio is less
than 5, the contrast would instead be considered a good candidate for a T1 contrasting; if larger than 5,
the agent may be more suitable for T2 contrasting [67].
Several r1 and r2 relaxivities from the literature are presented in Table 2, as well as the values
for the multistage magnetic-plasmonic structures from this work. Marangoni et al. [68] studied
the T1 relaxation of gold-core nanoparticles with a Gd(III) ion–silica layer, followed by a varied
gold shell. Interestingly, T1 contrast was better for the gold-based nanoparticles compared to the
typical Gd-based chelating agents. They also found that contrast was optimal for a gold-seeded shell
but was seen to decrease with additional gold growth. The authors suggest that the added mass
from the shell decreases the tumbling rate, hence decreasing the relaxivity for the thicker shelled
nanoparticles (worse contrast). Pinho et al. [69] studied the effect of silica shell thickness on the r1 and
r2 relaxivities of γ-Fe2O3 (see Table 2 for details). The thickness of silica had a significant impact on
both relaxivities, with increased shell thickness leading to a decrease in the relaxivity value (decreased
contrast). Others show the decrease in r1 [70] or decrease in both r1 and r2 [69,71] with the addition
of a SiO2 shell, similar to observations in this research with the addition of a gold shell. Moreover,
Park et al. noted a reduced r2 value for a diamagnetic avidin–biotin coating on Fe3O4 nanoparticles
and attributed this to diamagnetic shielding effects [72]. Assembled magnetic structures were also
seen to increase the r2 relaxation [73]. In this work, benchtop 1H NMR spectroscopy was used to
monitor the effects of the multistage magnetic-plasmonic nanoparticles on the relaxation of the water
associated peak at ca. 4.8 ppm. Information on the T1 and T2 measurement sequences can be found in
the experimental Section 2.3.
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Table 2. Relaxation properties of select examples from the literature, including SiO2 shells of varied thicknesses and magnetically assembled structures.





(MHz) Field (T) Ref.
Fe3O4 (20 nm) @Au (5 nm) - 181.35 - 1 3 [56]
Fe3O4 (20 nm) @Au (5 nm) + PEG 2 162.3 - 3 [56]
Fe3O4 9 nm + 1 nm SiO2 shell 94 - 3 [70]
Fe3O4 9 nm + 5 nm SiO2 shell 68 - 3 [70]
Fe3O4 9 nm + 10 nm SiO2 shell 47 - 3 [70]
Fe3O4 9 nm + 13 nm SiO2 shell 32 - 3 [70]






Fe2O3 ≈10 nm + ≈2 nm SiO2 shell 11.2 ≈100 ≈8.9 “ 3 “ [69]
Fe2O3 ≈10 nm + ≈8 nm SiO2 shell <2 ≈64 ≈32.0 “ “ [69]
Fe2O3 ≈10 nm + ≈15 nm SiO2 shell <2 ≈47 ≈23.5 “ “ [69]
Fe2O3 ≈10 nm + ≈20 nm SiO2 shell <2 ≈38 ≈19.0 “ “ [69]
Fe2O3 ≈10 nm + ≈28 nm SiO2 shell <2 ≈23 ≈11.5 “ “ [69]
Fe2O3 ≈10 nm + ≈52 nm SiO2 shell <2 ≈15 ≈7.5 “ “ [69]
Fe2O3 ≈10 nm + ≈67 nm SiO2 shell <2 ≈13 ≈6.5 “ “ [69]
Cluster core–shell Fe3O4 6 nm–APTES (≈96.6 nm total) 0.006 40.6 6766.7 300 7 [74]
Cluster core–shell Fe3O4 6 nm–GPTMS 4 (≈22.0 nm total) 0.026 14.4 553.8 300 7 [74]
Cluster core–shell Fe3O4 6 nm–TEOS 5 (≈66.6 nm total) 0.016 13.8 862.5 300 7 [74]
Fe3O4 (30 nm) with asymmetric surface chemistry (amine and thiol) - 44.87 - 1.4 [73]
Nanochains of Fe3O4 (30 nm) with amine and thiol surface - 101.05 - 1.4 [73]
Fe3O4 (11 nm)–CTAB 6 31.25 (13.69) 81.37 (82.18) 2.6 (6.0) 20 (60) 0.47 (1.41) [71]
Fe3O4 (12 nm) @mSiO2 shell (50 nm total) 3.65 (1.31) 84.26 (92.13) 23.1 (70.3) “ “ [71]
Fe3O4 (12 nm) @mSiO2 shell (75 nm total) 2.13 (0.97) 79.93 (87.54) 37.5 (90.3) “ “ [71]
Fe3O4 (12 nm) @mSiO2 shell (95 nm total) 0.61 (0.31) 50.13 (55.44) 82.2 (178.8) “ “ [71]
Fe3O4 (≈7.48 nm) ≈37 ≈48 ≈1.3 ≈10 - [75]
Fe3O4 (≈7.48 nm)–Au (5–8 nm) dimer ≈5 ≈62 ≈12.4 “ - [75]
Au core (5–8 nm)–Fe3O4 shell (≈15.92 nm total) ≈27 ≈41 ≈1.5 “ - [75]
Fe3O4 cluster (200 nm) - 230.7 - - [55]
Fe3O4 cluster (200 nm) + 5 nm Au seeds - 147.7 - - [55]
Fe3O4 cluster (200 nm) + 20 nm Au seeds - 163.1 - - [55]
Fe3O4 cluster (200 nm) + 25 nm Au shell - 158.2 - - [55]
Fe3O4 - 167 - - [76]
Fe3O4–Au (core–shell) - 61.9 - - [76]
Fe3O4–Au (yolk–shell) - 149.4 - - [76]
γ-Fe2O3 core–Au Shell ≈28.38 nm ≈8.82 (≈10.35) ≈4.04 (≈3.99) - (532 nm light) 100 µT [30]
20.5 ± 1.3 nm Fe3O4 (O) 0.92 32.70 35.55 60 1.5 This work
O + ≈3 nm Au seeds (Os) 0.72 21.94 30.56 “ “ “
O + ≈4 nm thick Au shell (R1) 0.66 15.43 23.27 “ “ “
O + ≈10.8 nm thick Au shell (R2) 0.29 15.06 51.48 “ “ “
O + ≈41.6 nm thick Au shell (R3) 0.24 13.58 55.48 “ “ “
1 Unknown quantity. 2 Polyethylene glycol. 3 Ditto marks indicate repeated values. 4 (3-Glycidyloxypropyl)trimethoxysilane. 5 Tetraethyl orthosilicate. 6 Cetyltrimethylammonium bromide.
Nanomaterials 2020, 10, 2424 9 of 16
From the data presented in Figure 3 and Table 2, we can conclude that the added gold has a
considerable impact on the relaxation properties of the iron oxide nanoparticles. Beginning with T1
properties, the iron oxide nanoparticles (O) have a r1 relaxivity of 0.92 mM−1 s−1; this reduces with
added gold to 0.24 mM−1 s−1 for the thick gold-shelled iron oxide nanoparticle (R3). In the case of
with T2 relaxation, there is also a reduction in the r2 relaxivity, which is 32.70 mM−1 s−1 for the bare
iron oxide (O) and 13.58 mM−1 s−1 for the iron oxide core with the thick gold shell (R3). Interestingly,
the r2/r1 ratio is minimum for the iron oxide nanoparticle with a thin gold shell (23.27) and maximum
for the thick gold-shelled iron oxide nanoparticle (55.48). This large ratio for the thick gold shell could
suggest that this stage is a good candidate for T2 imaging, but it is not paired with a high r2 value.
In summary, increasing the thickness of the gold shell reduces the relaxivity (increases the relaxation
time) for both T1 and T2 MRI imaging, hence reducing the contrasting capability.
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Figure 3. Nuclear magnetic resonance (NMR) of the various stages of magnetic-plasmonic
nanostructures. (A) shows the T1 relaxation time (s−1) of the various nanostructures at different
concentrations of iron (mM). (B) shows the graph of the T2 relaxation time with varied concentrations of
the multistage nanoparticles. (C,D) are bar graphs of the relaxivities r1 and r2, respectively. (E) shows
the r2/r1 ratio of the magnetic-plasmonic nanostructures.
3.3. Magnetic Hyperthermia
Hyperthermia therapy is a medical treatment that involves raising the temperature of the body in an
attempt to treat diseases such as cancer. Standard hyperthermia therapy may be delivered using infrared
light, microwaves, or radiofrequency. Like with other cancer treatments, there are adverse effects
when non-targeted tissue is affected, which can lead to blood clots or even cardiovascular issues [77].
The temperature to achieve cell death is debated, although most agree that 40–43 ◦C must be reached,
about 3–6 ◦C above healthy body temperature (37 ◦C) [77]. It is important to note that such therapy is not
a conventional therapy, and would rarely be used as the first choice for treatment due to non-selective
heating. To combat issues with non-selective heating, nanoparticle agents have been proposed as a
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technique for localizing the heat to targeted areas with minimal heating of the surrounding healthy
tissue. One such nanoparticle agent is magnetic nanoparticles. Magnetic hyperthermia combines
magnetic nanoparticles with an external high-frequency alternating magnetic field. To achieve selective
heating, the nanoparticle should target the tumor site, using either passive or, preferably, active targeting
techniques (using targeting ligands, magnetic field).
Typically, superparamagnetic nanoparticles are used as magnetic hyperthermia agents.
Superparamagnetic nanoparticles flip to align their magnetic dipole to the external magnetic field
orientation. When this magnetic field is alternating, and at a high frequency, these nanoparticles flip to
orient with the field but lose power due to hysteresis, resulting in heat dissipation.
In an AC magnetic field, the magnetization of the nanoparticle may not be responsive enough to
keep up with the AC frequency, resulting in a phase difference. This phase difference requires a complex
magnetic susceptibility explanation. The concentration, size, and material of the nanomaterial impact
the hyperthermia activity along with the field strength and frequency. Furthermore, magnetic assembly
leads to higher hysteresis losses, thus increasing the heat generated [78]. A silica shell [79,80] and a
polyphosphazene–gold shell [81] have also been shown to decrease magnetic hyperthermia activity.
To benchmark the heating efficiency of the magnetic-plasmonic nanoparticles, the specific power
absorption (SPA) (W/g), also known as the specific absorption rate (SAR), is calculated per [82].
Furthermore, to account for the magnetic field strength and frequency used, the intrinsic loss power
parameter (ILP) (H m2 kg−1) is calculated per [82].
From Figure 4 and Table 1, we can deduce that the addition of gold leads to a reduction in the
magnetic hyperthermia activity. As previously discussed, it is likely that with the addition of gold there
is a reduction of interparticle assembly as this formation is linked closely with an increased magnetic
hyperthermia activity. The heating efficiency of commercial magnetic colloids has been reported to be
between 0.15 and 3.12 nH m2/kg Fe [12]. Therefore, the magnetic-plasmonic nanoparticles in this study
are comparable until thicker gold shells are added (R2 and R3).
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In this work, the following five stages of magnetic-plasmonic nanoparticles were studied:
Fe3O4 nanoparticles (O), Fe3O4–Au core–satellite nanostructures (Os), Fe3O4–Au with thin gold shell
(R1), Fe3O4–Au with intermediate thickness gold shell (R2), and Fe3O4–Au with thick gold shell
(R3). These nanoparticle stages were studied in three applications—magnetophoresis, MRI or NMR
contrasting, and magnetic hyperthermia.
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The magnetophoresis rate of magnetic-based nanostructures is key in magnetic field-driven
drug delivery, magnetic sorting, and other applications requiring magnetic manipulation. It was
found that increased gold coating leads to a reduction in the magnetophoresis rate, rendering the
nanoparticle less responsive to magnetic fields. The magnetophoresis speed is reduced to ca. 1% for
the thickest gold shell compared to the uncoated iron oxide nanoparticle (see Table 1 for further details).
The magnetophoresis speed decreases exponentially (see Figure 5) with increased gold shell thickness;
thus, if responsivity is required for the application, a thinner gold coating is preferable. We attribute
this reduced responsivity of the increased gold shell thickness to a reduced magnetic saturation, loss of
cooperative behavior, and increased drag forces.
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Figure 5. Exponential dependency of the normalized NMR relaxivities r1 and r2, the specific power
absorption (SPA), and the magnetophoresis speed (vmag) as a function of gold shell thickness. See Table 1
for values.
Iron oxide nanoparticles are commonly used as MRI contrast agents, specifically as T2 agents.
In this work, the T1 and T2 relaxivities (r1 and r2) of the various magnetic-plasmonic nanostructures were
measured. As with the magnetophoresis, the T1 and T2 relaxivities, r1 and r2, decreased exponentially
with additional gold growth (see Table 1). Compared to the purely magnetic counterpart, the thickest
gold shell has a reduced relaxivity, to 22.2% and 41.6% for r1 and r2, respectively. These relaxivities also
decreased exponentially (see Figure 5) with increased gold shell thickness (see Figure 5). We attribute
this decreased relaxivity of thicker gold shells to reduced magnetic saturation, loss of cooperative
behavior, and reduced exchange interaction with water nuclei.
Lastly, increasing the gold content of the magnetic-plasmonic hybrid nanoparticles led to an
exponential decrease (see Figure 5) in the specific power absorption of the nanoparticles undergoing
magnetic hyperthermia. A reduction to 14.3% was seen for the intrinsic loss power parameter,
a measurement of heating efficiency that considers magnetic field strength and frequency, for the
thickest gold shell on the magnetic core compared to the purely magnetic nanoparticle. This reduced
heating efficiency with gold addition is likely a result of reduced cooperative behavior along with
reduced magnetic saturation.
5. Conclusions
In conclusion, increasing the gold shell thickness has a significant reduction in the magnetophoresis
rate, T1 and T2 contrast, and magnetic hyperthermia activity of iron oxide nanoparticles. A number
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of factors are likely responsible for this reduced activity with increased gold shell thickness.
We hypothesize that less cooperation due to reduced dipole–dipole magnetic interaction forces
and a reduced magnetic saturation owing to the decreased magnetic volume and possible diamagnetic
magnetic shielding by the gold shell are predominantly responsible.
In a previous work ([28]), we demonstrated that the thinner gold shells (R1 and R2) exhibit a large
spectral drift between the optical absorption (highest photothermal activity) and the optical scattering
(strongest optical imaging contrast). We demonstrate in this work that these thinner gold shells are also
better for magnetic-based applications. Hence, this work further emphasizes that a thick gold shell is
not necessary to achieve a highly functional nanotheranostic nanoplatform. In other words, thinner gold
coating appears preferable in an extending series of both magnetic- and light-based applications.
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